Anteris Technologies Global Corp. (NASDAQ:AVR) Financings

Anteris Technologies Global Corp.

Financings

RaiseDate
Public offering of common stock
Closed: US$200M raised · US$5.75 a share · Barclays +3
Dealers: Barclays (co-lead), Wells Fargo Securities (co-lead), Cantor (co-lead), Barrenjoey Markets Pty Limited
Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve
Jan 22, 2026
Strategic investment of common stock
Closed: US$90M raised · Wells Fargo Securities
Dealers: Wells Fargo Securities (lead)
Buyers: Medtronic plc (up to $90.0 million of shares, 16.0% to 19.99% of shares outstanding after the Offering); Medtronic, plc ($90 million strategic investment)
Use of proceeds: To support the global pivotal PARADIGM trial and advance toward global commercialization of the DurAVR Transcatheter Heart Valve
Jan 22, 2026

Read by 6ix AI from the company's releases